Pharmaceutical Technology

JANUARY 23, 2023

As such, the SLE and LN marketplace is dominated by generics, and GSK’s Benlysta and AstraZeneca’s Saphnelo are the only drugs that have gained marketing approval specifically for SLE in more than 50 years. In previous years, Benlysta has managed to grow the lupus market in terms of value, having generated approximately $492.9m

Marketing 278

Marketing Production Drugs Trials 278

Pharmaceutical Technology

JUNE 19, 2023

Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar. Biomm will gain exclusive rights for the distribution and marketing in Brazil of the proposed biosimilar to Janssen’s Stelara.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

Pharmaceutical Technology

APRIL 27, 2023

The European Commission’s (EC) long-anticipated pharma reform plans in the European Union have finally been unveiled , indicating a focus on improving access to medicines across the bloc while cutting down on market exclusivity. Along with the patent-related changes, the EC is seeking to ease some of the regulatory steps.

Marketing 264

Marketing Medicine Production Clinical Trials 264

Bio Pharma Dive

AUGUST 1, 2023

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

Licensing 130

Licensing Licensing Drugs Production 130

Pharmaceutical Technology

DECEMBER 20, 2022

The European Commission (EC) has granted marketing authorization for Atara Biotherapeutics’ Ebvallo (tabelecleucel) as a monotherapy to treat Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) patients. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Marketing 298

Marketing Gene Therapy Gene Medicine 298

Drug Discovery World

AUGUST 2, 2023

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. ” The post Renaissance Pharma licenses Hu14.18

Licensing 98

Licensing Licensing Antibody Trials 98

Pharmaceutical Technology

JANUARY 23, 2023

Takeda has signed an exclusive licence agreement with HUTCHMED (China) and its subsidiary HUTCHMED to develop and market the latter’s fruquintinib. The China National Medical Products Administration (NMPA) approved fruquintinib for marketing in September 2018.

Licensing 130

Licensing Licensing Sales Branding 130

Pharmaceutical Technology

JULY 28, 2022

Melinta Therapeutics has signed a licence agreement with Cidara Therapeutics to facilitate a strategic collaboration for marketing the latter’s rezafungin in the US. The post Melinta and Cidara sign licensing deal for rezafungin appeared first on Pharmaceutical Technology.

Licensing 147

Licensing Licensing Clinical Trials Clinical Trials 147

Pharmaceutical Technology

DECEMBER 9, 2022

Brazil is the largest country in Latin America, with a population of over 212 million, and consequently has the biggest pharmaceutical market in the region. Advantages of joining PIC/S include the adoption of codes that should reduce the number of audits required for some products, accelerating their time to market.

Marketing 246

Marketing Sales Production Medicine 246

Pharmaceutical Technology

MARCH 17, 2023

Pharmanovia and Aeterna Zentaris have entered an exclusive licensing agreement for the latter’s medicine Ghryvelin (macimorelin). Under the deal, Pharmanovia will acquire the exclusive rights and license to commercialise Ghryvelin in the EEA and the UK from Consilient Health.

Hormones 263

Hormones Licensing Licensing Medicine 263

Pharmaceutical Technology

MAY 3, 2023

Aurinia Pharmaceuticals has received marketing authorisation from the Swiss Agency for Therapeutic Products (Swissmedic) for Lupkynis (voclosporin), along with a background immunosuppressive therapy. This promotes podocyte stability in the kidneys. Lupkynis has also received orphan drug designation in Switzerland.

Marketing 130

Marketing Licensing Licensing Production 130

Pharmaceutical Technology

MAY 22, 2023

Biogen and Eisai have submitted a marketing authorisation application (MAA) to the UK’s medicines and healthcare products regulatory agency (MHRA) for lecanemab to treat early Alzheimer’s disease (AD). The regulator has also designated the therapy for the innovative licensing and access pathway (ILAP).

Marketing 130

Marketing Antibody Licensing Licensing 130

Pharmaceutical Technology

MAY 8, 2023

Under the terms of the license and commercialisation deal, Dr. Reddy’s will get licence for the development and commercialisation of toripalimab in India, Panama, Peru, Colombia, South Africa, Brazil, Argentina, Chile, Uruguay, and Mexico. Junshi Biosciences may get an aggregate of up to $728.3m

Development 130

Development Marketing Licensing Licensing 130

Fossil Remedies

OCTOBER 16, 2022

In a pharma business, you have a distribution network like a pharma manufacturing company, pharma marketing company, C&F agents, wholesalers/distributors/stockiest, retailers, and pharmacies. To launch the best PCD pharma franchise company, you will have to acquire the necessary licenses from authorities. Wholesale Drug License.

Licensing 52

Licensing Licensing Pharma Companies Cosmetics 52

Camargo

DECEMBER 15, 2020

Whether a sponsor develops a new product or plans to license an exciting new asset developed somewhere else, commercial success or failure will depend on its understanding of the market and ability to develop an effective commercial strategy. How big is the addressable market, and what do I know about it?

Production 170

Production Marketing Development Doctors 170

Pharmaceutical Technology

JANUARY 19, 2023

Acute myeloid leukemia (AML) is part of a market of blood malignancies that commercial cell therapies have not managed to penetrate yet. GlobalData’s Pharma Intelligence Center shows 19 autologous CAR-T cell products in Phase I, and nine products in Phase II, globally.

Marketing 130

Marketing Gene Editing Production Sales 130

Pharmaceutical Technology

JUNE 5, 2023

PharmaEssentia may be entitled to receive certain milestone payments along with royalties based on sales of the product. Pint-Pharma will obtain and maintain all marketing authorisations and will commercialise BESREMi in the region. It holds orphan drug designation in the US to treat PV.

Marketing 130

Marketing Licensing Licensing Sales 130

Pharmaceutical Technology

MAY 2, 2023

As per the agreement, BMS could exercise opt-in rights for any of the four TCR-T product candidates being developed by Immatics. This news comes a few weeks after BMS signaled an increased focus on cell therapy manufacturing with a takeover of former Novartis plant to boost viral vector production for T-cell therapies.

Licensing 130

Licensing Licensing Gene Editing Development 130

Fossil Remedies

JANUARY 19, 2022

But do we know which PCD products should we pick so that the maximum profitability is ensured? This blog is an attempt to clarify the concepts about choosing the best products. Points to consider while choosing products. Always pick products that you are comfortable with. Legally identified products. Perhaps no.

Production 98

Production Pharma Companies Pharma Production Marketing 98

Pharmaceutical Technology

MAY 31, 2023

Stealth BioTherapeutics has made an exclusive licensing agreement with Pharmanovia for the commercialisation of its elamipretide to treat Barth syndrome. The investigational product candidate has concluded Phase III development as a treatment option for Barth syndrome.

Licensing 245

Licensing Licensing Sales Development 245

BioPharma Reporter

JULY 6, 2022

Touchlight has agreed to a non-exclusive patent license for Pfizer to utilize its enzymatic doggybone DNA (dbDNA).

DNA 52

DNA Licensing Licensing Production 52

pharmaphorum

MAY 17, 2021

UK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to develop novel formulations of insulins and other biological drugs with enhanced properties. Arecor has four active licensing agreement in place with partners including Hikma and Inhibrx.

Insulin 52

Insulin Production Marketing Pharma Companies 52

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2.

Antibody 98

Antibody Marketing Drugs Licensing 98

Pharmaceutical Technology

JANUARY 25, 2023

After a tumultuous year that weathered the continued impact of a bear market , many in biotech are looking for signs of improvement in 2023. A game of musical chairs Lyne compares the current situation to a game of musical chairs, where the status of each company essentially depends on where they were positioned when the market shifted.

Marketing 173

Marketing Life Science Pharma Companies Licensing 173

XTalks

JANUARY 29, 2021

Oncology products monopolise the list of best-selling drugs. Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products.

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

Pharmaceutical Technology

OCTOBER 21, 2022

On concluding this trial, Roche will gain the right to develop and market the licenced products across various indications, contingent on approval. Roche also holds an option for licensing second arenaviral cancer immunotherapy. According to the agreement, Roche will make $25m in upfront payment to Hookipa. .

Development 278

Development Production Licensing Licensing 278

pharmaphorum

OCTOBER 28, 2022

The sooner a human-centred perspective is applied to the development of either a drug or device product, the more likely the product will be adopted and used because it’s been designed around what the end consumer wants and needs. This will ensure that you are developing a product these audiences will use.

Life Science 92

Life Science Production Development Drugs 92

Cloudbyz

AUGUST 2, 2022

Premarketing drug studies vs Post- Marketing research. Approximately only 20 % of the drugs that enter phase I are approved for marketing. Post-marketing research is a generic term used to describe all activities after drug approval by the regulatory agencies, such as the Food and Drug Administration (FDA).

Marketing 78

Marketing Research Clinical Trials Clinical Trials 78

Pharmaceutical Technology

NOVEMBER 28, 2022

C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. on meeting clinical development and commercial milestones in the future, in addition to tiered royalty payments, upon the marketing of the product.

Development 264

Development Gene Expression Licensing Licensing 264

Pharmaceutical Technology

MAY 1, 2023

Nicox’s Chinese partner Ocumension Therapeutics has secured priority review status for the New Drug Application (NDA) for Zerviate (cetirizine ophthalmic solution), 0.24%, from China’s National Medical Products Administration (NMPA). It has been approved to treat ocular itching that is associated with allergic conjunctivitis in the US.

Licensing 162

Licensing Licensing Sales Packaging 162

Druggist

DECEMBER 17, 2020

Without a doubt, codeine-containing products are one of the most commonly sold medicines in the UK. Most codeine products are combination products of codeine and another drug. Restrictions on the supply of codeine-containing products. Codeine over the counter: UK list of products. Prescription-only codeine.

Production 98

Production Containment Pharmacy Licensing 98

Roots Analysis

AUGUST 7, 2023

Moreover, cell based biomanufacturing imposes inherent limitations on the effective production of biologics. Given the growing demand for biologic products, cell free expression has become a key focus area for stakeholders in the biopharmaceutical industry. Interestingly, most of these kits are used for cell-free protein expression.

Marketing 52

Marketing Protein In-Vitro Production 52

Pharmaceutical Technology

DECEMBER 19, 2022

On choosing the candidate, the company will oversee the complete development, production and marketing. Initially, the companies signed a research collaboration and licensing agreement in 2016 to develop and assess up to two bispecific NK cell engagers.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

Druggist

NOVEMBER 10, 2020

Today I will list Calpol alternative products, including other brands and forms of liquid paracetamol and alternative drugs. Although the intention is to find Calpol alternative products for toddlers and children, I included a few products, which have a minimum age restriction of 12 years and above. Calpol alternative products.

Production 98

Production Pharmacy Containment Branding 98

Pharmaceutical Technology

AUGUST 1, 2022

The human health product candidates of GreenLight are currently in the pre-clinical stage. In March, the company entered a licensing agreement with Serum Institute of India (SII) to expedite access to messenger RNA products in emerging markets worldwide.

Vaccination 245

Vaccination Vaccine Development RNA 245

pharmaphorum

NOVEMBER 22, 2022

Germany’s Merck KGaA has said it needs to double the productivity of its R&D operations, with the aim of launching a new product every 18 months on average, to boost its pharma business. The post Merck pledges revamp of R&D to drive productivity appeared first on.

Production 52

Production Licensing Licensing Antibody 52

Fierce Pharma

APRIL 4, 2024

. | Teva has unveiled a fresh in-licensing accord with Spain’s mAbxience to chip in on an investigational biosimilar spanning multiple oncology indications.

Licensing 82

Licensing Licensing Manufacturing Production 82